Early differences in dorsal hippocampal metabolite levels in males but not females in a transgenic rat model of alzheimer's disease

Neurochemical Research

Volumn 39, Issue 2, 2014, Pages 305-312

  Nilsen, L H ^a   Melo T M ^a   Witter, M P ^a,b   Sonnewald, U ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Animal model; Gender; Glutamate; Metabolism; MR spectroscopy

Indexed keywords

ALZHEIMER DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; HIPPOCAMPUS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; RATS; RATS, TRANSGENIC; SEX FACTORS;

EID: 84895100674     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-013-1222-x     Document Type: Article

References (42)

1. Mosconi L et al (2006) Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J Nucl Med 47(11):1778-1786
2. Serrano-Pozo A et al (2011) Neuropathological alterations in Alzheimer disease. In: Mandelkow E, Holtzman DM, Selkoe DJ (eds) The biology of alzheimer disease. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp 43-65
3. Tiwari V, Patel AB (2012) Impaired glutamatergic and GABAergic function at early age in AbetaPPswe-PS1dE9 mice: implications for Alzheimer's disease. J Alzheimers Dis 28(4):765-769
4. LaFerla FM, Green KN, Oddo S (2007) Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 8(7):499-509
5. Lloret A et al (2008) Gender and age-dependent differences in the mitochondrial apoptogenic pathway in Alzheimer's disease. Free Radic Biol Med 44(12):2019-2025
6. Nilsen J et al (2006) Estrogen protects neuronal cells from amyloid beta-induced apoptosis via regulation of mitochondrial proteins and function. BMC Neurosci 7:74
7. Godbolt AK et al (2006) MRS shows abnormalities before symptoms in familial Alzheimer disease. Neurology 66(5):718-722
8. Kantarci K, Jack CR Jr (2003) Neuroimaging in Alzheimer disease: an evidence-based review. Neuroimaging Clin N Am 13(2):197-209
9. Mueller SG et al (2010) Hippocampal atrophy patterns in mild cognitive impairment and Alzheimer's disease. Hum Brain Mapp 31(9):1339-1347
10. Celone KA et al (2006) Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. J Neurosci 26(40):10222-10231
11. Wang Z et al (2009) Regional metabolic changes in the hippocampus and posterior cingulate area detected with 3-Tesla magnetic resonance spectroscopy in patients with mild cognitive impairment and Alzheimer disease. Acta Radiol 50(3):312-319
12. Shiino A et al (2012) The profile of hippocampal metabolites differs between Alzheimer's disease and subcortical ischemic vascular dementia, as measured by proton magnetic resonance spectroscopy. J Cereb Blood Flow Metab 32(5):805-815
13. Wiame E et al (2010) Molecular identification of aspartate N-acetyltransferase and its mutation in hypoacetylaspartia. Biochem J 425(1):127-136
14. Narayanan S et al (2001) Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 248(11):979-986
15. Gasparovic C et al (2001) Decrease and recovery of N-acetylaspartate/ creatine in rat brain remote from focal injury. J Neurotrauma 18(3):241-246
16. Eng LF, Ghirnikar RS, Lee YL (2000) Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochem Res 25(9-10):1439-1451
17. Chen SQ et al (2009) Role of myo-inositol by magnetic resonance spectroscopy in early diagnosis of Alzheimer's disease in APP/PS1 transgenic mice. Dement Geriatr Cogn Disord 28(6):558-566
18. Bitsch A et al (1999) Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am J Neuroradiol 20(9):1619-1627
19. Rupsingh R et al (2011) Reduced hippocampal glutamate in Alzheimer disease. Neurobiol Aging 32(5):802-810
20. Watanabe T, Shiino A, Akiguchi I (2010) Absolute quantification in proton magnetic resonance spectroscopy is useful to differentiate amnesic mild cognitive impairment from Alzheimer's disease and healthy aging. Dement Geriatr Cogn Disord 30(1):71-77
21. Leon WC et al (2010) A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment. J Alzheimers Dis 20(1):113-126
22. Nilsen LH et al (2012) Altered neurochemical profile in the McGill-R-Thy1-APP rat model of Alzheimer's disease: a longitudinal in vivo (1) H MRS study. J Neurochem 123(4):532-541
23. Bottomley PA (1987) Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci 508:333-348
24. Tkac I et al (1999) In vivo 1H NMR spectroscopy of rat brain at 1 ms echo time. Magn Reson Med 41(4):649-656
25. Gruetter R (1993) Automatic, localized in vivo adjustment of all first- and second-order shim coils. Magn Reson Med 29(6):804-811
26. Provencher SW (1993) Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30(6):672-679
27. Tkac I et al (2003) Developmental and regional changes in the neurochemical profile of the rat brain determined by in vivo 1H NMR spectroscopy. Magn Reson Med 50(1):24-32
28. De Souza SW, Dobbing J (1971) Cerebral edema in developing brain. I. Normal water and cation content in developing rat brain and postmortem changes. Exp Neurol 32(3):431-438
29. Klein J (2000) Membrane breakdown in acute and chronic neurodegeneration: focus on choline-containing phospholipids. J Neural Transm 107(8-9):1027-1063
30. Jansen JF et al (2006) 1H MR spectroscopy of the brain: absolute quantification of metabolites. Radiology 240(2):318-332
31. Kreis R (2004) Issues of spectral quality in clinical 1H-magnetic resonance spectroscopy and a gallery of artifacts. NMR Biomed 17(6):361-381
32. Hong, ST and Pohmann R (2012) Quantification issues of in vivo (1) H NMR spectroscopy of the rat brain investigated at 16.4 T. NMR Biomed
33. Foy CM et al (2011) Hippocampal proton MR spectroscopy in early Alzheimer's disease and mild cognitive impairment. Brain Topogr 24(3-4):316-322
34. Canadian study of health and aging (1994) Study methods and prevalence of dementia. CMAJ 150(6):899-913
35. Andersen K et al (1999) Gender differences in the incidence of AD and vascular dementia: the EURODEM studies. EURODEM incidence research group. Neurology 53(9):1992-1997
36. Wang J et al (2003) Gender differences in the amount and deposition of amyloidbeta in APPswe and PS1 double transgenic mice. Neurobiol Dis 14(3):318-327
37. Ottersen OP, Zhang N, Walberg F (1992) Metabolic compartmentation of glutamate and glutamine: morphological evidence obtained by quantitative immunocytochemistry in rat cerebellum. Neuroscience 46(3):519-534
38. Marjanska M et al (2005) Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc Natl Acad Sci USA 102(33):11906-11910
39. Dedeoglu A et al (2004) Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res 1012(1-2):60-65
40. von Kienlin M et al (2005) Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span. Neurobiol Dis 18(1):32-39
41. Oberg J et al (2008) Age related changes in brain metabolites observed by 1H MRS in APP/PS1 mice. Neurobiol Aging 29(9):1423-1433
42. Haussinger D et al (1994) Proton magnetic resonance spectroscopy studies on human brain myo-inositol in hypo-osmolarity and hepatic encephalopathy. Gastroenterology 107(5):1475-1480